RARE DISEASE & ORPHAN DRUG COMMERCIALIZATION
A novel approach.
for novel therapies.
Your rare disease therapy can't be commercialized like a blockbuster drug. Actum Pharma is purpose-built for the unique funding, payer, patient support, and distribution challenges that orphan and complex therapies face—so life-changing treatments actually reach patients.
THE PROBLEMS WE SOLVE
Great science shouldn't fail for
avoidable commercial reasons.
Orphan and rare disease therapies face challenges that standard commercialization playbooks weren't designed for. We plan alongside you—early—so these don't become surprises.
-
We align your funding narrative with the unique capital expectations of rare disease—so your science gets the runway it deserves.
-
We build contingency into your capital plan so a regulatory setback doesn't become an existential crisis.
-
Rare disease doesn't follow the standard launch playbook. We identify the right path—before you've spent resources on the wrong one.
-
Misaligned teams cause costly delays. We map every education moment and operational handoff from clinical through commercial.
-
The wrong distribution model can stall patient access or erode profitability. We evaluate the tradeoffs specific to your drug and patient.
-
We build analytics into your patient support and distribution programs so you can course-correct before problems compound.
OUR APPROACH
An operating partner model, not just another consultant
"We fill the gaps. We plan alongside you. We reduce risk."
The biopharma ecosystem is crowded with vendors focused on narrow slices of the drug journey. Actum takes a holistic view of what it takes for complex, orphan drugs to achieve commercial success—and we embed experienced operators alongside your team from the earliest stages.
Whether you need a strategic thought partner on speed dial or full-scale program management, we deploy expert operational support at every stage, particularly in the non-clinical areas that so often derail great science in rare disease.
We're not a traditional consultancy pushing services. We're a flexible, financially-minded partner built to shore up gaps in expertise and execution.
| Capability | Common Drug Model | Actum Model |
|---|---|---|
| Capital Strategy | Not typically included | Integrated from day one |
| Commercial Planning | Generic playbook | Rare-disease specific |
| Patient Population Size | Mass-market focus | Built for small populations |
| Engagement Timing | Post-approval | Clinical stage & earlier |
| Distribution Model | Standard SP network | Fit-for-purpose design |
| Flexibility | Fixed service packages | Modular, gap-filling |
WHAT WE DO
Expert support, exactly where you need it
From funding through launch and beyond, Actum deploys integrated capabilities that address the distinct commercial challenges of rare disease therapies.
FUND
Capital Strategy
MANAGE
Fundraising and capital management aligned to the unique investor landscape for rare disease. We help you build the cash runway and contingency plans your science deserves.
PLAN
Commercialization Planning
Market analysis, HCP strategy, and payer frameworks uniquely designed for your disease, patient population, and product attributes—not a generic template.
Patient-Product Journey Mapping
An optimized pathway for product and patient, accounting for disease characteristics, supply chain complexity, stakeholder education, and adherence needs.
MARKET
Distribution & Patient Services
Fit-for-purpose distribution design—SP selection, handling, and analytics—paired with a "patient-first" branded HUB program covering benefits investigation, prior authorization, copay assistance, and adherence.
CLIENT ANECDOTES
Rare disease success stories
CLINICAL STAGE · RARE SKIN CONDITION
Navigating a Phase 3 setback without losing commercial momentum
A clinical-stage company experienced a Phase 3 setback that was clinically addressable, but threatened its cash position and future viability—despite its promising rare-disease therapy. Actum stepped in to provide early commercial guidance, capital strategy support, and helped the team design and launch an Expanded Access Program that sustained momentum and investor confidence through the setback.
CELL & GENE THERAPY · FIRST-OF-ITS-KIND
Building a tightly orchestrated patient HUB for a first-of-its-kind therapy
A first-time cell and gene therapy manufacturer needed a partner to create a highly supportive patient HUB experience for a landmark therapy for a rare genetic skin condition. Actum worked alongside the commercial team throughout Phase 3, building a patient-product journey map and distribution strategy that simplified a highly complex intervention for patients, caregivers, QTCs and payers—culminating in a branded program with a dedicated team of highly credentialed staff.
WHO WE SERVE
Built for the innovators who need us most
Actum works with clinical-stage biopharma companies, investors, and strategic partners focused on rare disease, orphan drugs, and complex conditions.
Investors & Strategic Partners
VCs and strategic investors focused on the success of portfolio companies—preventing avoidable failures and setbacks through a financially-minded, flexible operating partner that shores up gaps in expertise and execution.
Clinical Stage Biopharma Manufacturers
Small teams, founder-led companies focused on rare and complex conditions who need an experienced commercial partner to steer toward the best outcome—given market conditions and commercialization complexity.
LET'S TALK
Your novel therapy needs a novel commercial plan
Whether you're in clinical development or approaching launch, Actum helps you build the right strategy—before the wrong one costs you time, capital, and patient access.